Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Biosimilar rituximab (PF-05280586)
print preview
bookmark
share with colleague
General Information
Company
Pfizer Inc.
Description
Biosimilar of rituximab
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase I/II
Indication
Rheumatoid arthritis (RA)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information